CoChat

Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Open access
Zander, Thomas, Scheffler, Matthias, Nogova, Lucia, Kobe, Carsten, Engel-Riedel, Walburga, Hellmich, Martin, Papachristou, Irini, Toepelt, Karin, Draube, Andreas, Heukamp, Lukas, Buettner, Reinhard, Ko, Yon D., Ullrich, Roland T., Smit, Egbert, Boellaard, Ronald, Lammertsma, Adriaan A., Hallek, Michael, Jacobs, Andreas H., Schlesinger, Andreas, Schulte, Karin, Querings, Silvia, Stoelben, Erich, Neumaier, Bernd, Thomas, Roman K., Dietlein, Markus, Wolf, Jürgen · 2011 · Journal of Clinical Oncology
Cited by 170

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Positron emission tomography (PET) with both 2′-deoxy-2′-[18 F]fluoro-d-glucose (FDG) and 3′-[18 F]fluoro-3′-deoxy-l-thymidine (FLT) was evaluated with respect to the accuracy of early prediction of nonprogression following erlotinib therapy, independent from epidermal growth factor receptor (EGFR) mutational status, in patients with previously untreated advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Thirty-four patients with untreated stage IV NSCLC were evaluated in this phase II trial. Changes in FDG and FLT uptake after 1 (early) and 6 (late) weeks of erlotinib treatment were compared with nonprogression measured by computed tomography after 6 weeks of treatment, progression-free survival (PFS), and overall survival (OS). Results: Changes in FDG uptake after 1 week of therapy predicted nonprogression after 6 weeks of therapy with an area under the receiver operating characteristic curve of 0.75 (P = .02). Furthermore, patients with an early metabolic FDG response (cutoff value: 30% reduction in the peak standardized uptake value) had significantly longer PFS (hazard ratio [HR], 0.23; 95% CI, 0.09 to 0.59; P = .002) and OS (HR, 0.36; 95% CI, 0.13 to 0.96; P = .04). Early FLT response also predicted significantly longer PFS (HR, 0.31; 95% CI, 0.10 to 0.95; P = .04) but not OS and was not predictive for nonprogression after 6 weeks of therapy. Conclusion: Early FDG-PET predicts PFS, OS, and nonprogression after 6 weeks of therapy with erlotinib in unselected, previously untreated patients with advanced NSCLC independent from EGFR mutational status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.32.4939

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 170

Metadata

Authors
Zander, T., Scheffler, M., Nogova, L., Kobe, C., Engel-Riedel, W., Hellmich, M., Papachristou, I., Toepelt, K., Draube, A., Heukamp, L., Buettner, R., Ko, Y. D., Ullrich, R. T., Smit, E., Boellaard, R., Lammertsma, A. A., Hallek, M., Jacobs, A. H., Schlesinger, A., Schulte, K., Querings, S., Stoelben, E., Neumaier, B., Thomas, R. K., Dietlein, M., & Wolf, J.
Venue
Journal of Clinical Oncology
Published
2011-05-01
Volume
29
Issue
13
Pages
1701-1708
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2053846938
Cited by
170
References
5
FWCI
20.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography. https://app.cochat.ai/papers/10.1200/jco.2010.32.4939
The paper
Zander, T., Scheffler, M., Nogova, L., Kobe, C., Engel-Riedel, W., Hellmich, M., Papachristou, I., Toepelt, K., Draube, A., Heukamp, L., Buettner, R., Ko, Y. D., Ullrich, R. T., Smit, E., Boellaard, R., Lammertsma, A. A., Hallek, M., Jacobs, A. H., Schlesinger, A., . . . Wolf, J. (2011). Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.32.4939

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.